Reproductive Viability of Cells Following Preoperative Stereotactic Ablative Radiotherapy
We read with interest the article published by Palma et al reporting a phase 2 clinical trial of preoperative stereotactic ablative radiation therapy (SABR) plus surgery in patients with early stage non-small cell lung cancer (NSCLC).1 Surgery was implemented in 10 weeks after SABR. The authors concluded that the pathologic complete response (pCR) rate after SABR was 60%, which was lower than the hypothesized 90% pCR rate. Preoperative SABR and surgery combination did not increase toxicity more than surgery alone, and there was no perioperative mortality.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Mahmut Ozsahin, Ben J. Slotman, Jean Bourhis Tags: Comment Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Physics | Radiation Therapy | Radiology | Toxicology